In one sense, Veklury (remdesivir) is not a new drug.
Gilead Sciences initially developed remdesivir (GS-5734) in reaction to the 2014 Ebola outbreak. The drug remained investigational, however, until the COVID-19 pandemic.
In 2020, it became the first FDA-approved drug to treat COVID-19. Last year, it raked in $2.811 billion in revenue.
Filed Under: Infectious Disease